Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2023.2203812
Abstract: BACKGROUND Biosimilar adalimumabs have improved treatment access, but without any clinical advantage, distributors rely on delivery device design-enhancements, support services, and removal of painful excipients to capture market share. Prescribers, however, are often unaware of… read more here.
Keywords: originator versus; adalimumab biosimilars; versus adalimumab; adalimumab ... See more keywords
Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15803
Abstract: In the last years, adalimumab biosimilars have represented a commonly used alternative to the originator agent in the treatment of moderate to severe hidradenitis suppurativa. As of today, studies investigating the switch from adalimumab originator… read more here.
Keywords: adalimumab originator; switch; switching adalimumab; originator biosimilars ... See more keywords
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10102522
Abstract: This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness.… read more here.
Keywords: originator biosimilar; treatment; adalimumab originator; originator ... See more keywords
Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
Sign Up to like & getrecommendations! Published in 2022 at "Life"
DOI: 10.3390/life12101518
Abstract: Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO… read more here.
Keywords: adalimumab originator; registry; hidradenitis suppurativa; originator ... See more keywords